Wenjin Yang
Director Técnico/Científico/I+D en FORESEE PHARMACEUTICALS CO., LTD. .
Cargos activos de Wenjin Yang
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FORESEE PHARMACEUTICALS CO., LTD. | Director Técnico/Científico/I+D | 21/09/2015 | - |
Historial de carrera de Wenjin Yang
Antiguos cargos conocidos de Wenjin Yang.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Director Técnico/Científico/I+D | 01/01/2011 | - |
Fundador | 01/01/2011 | - | |
The Scripps Research Institute
The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | - | - |
VIRACTA THERAPEUTICS, INC. | Director/Miembro de la Junta | - | - |
Corporate Officer/Principal | - | - | |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - | - |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01/03/2010 | - |
Formación de Wenjin Yang.
National Taiwan University | Doctorate Degree |
University of California, Berkeley | Doctorate Degree |
Chinese Culture University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Taiwán | 4 |
Operativa
Corporate Officer/Principal | 4 |
Doctorate Degree | 2 |
Undergraduate Degree | 2 |
Sectorial
Health Technology | 6 |
Consumer Services | 5 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
FORESEE PHARMACEUTICALS CO., LTD. | Health Technology |
Empresas privadas | 3 |
---|---|
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Wenjin Yang
- Experiencia